These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25247952)

  • 1. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
    D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
    AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor load in patients with multiple myeloma: β₂-microglobulin levels versus low-dose whole-body CT.
    Pfahler V; D'Anastasi M; Dürr HR; Schinner R; Ricke J; Baur-Melnyk A
    Eur J Haematol; 2020 May; 104(5):383-389. PubMed ID: 31762076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body MRI of multiple myeloma: comparison of different MRI sequences in assessment of different growth patterns.
    Weininger M; Lauterbach B; Knop S; Pabst T; Kenn W; Hahn D; Beissert M
    Eur J Radiol; 2009 Feb; 69(2):339-45. PubMed ID: 18096344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?
    Baur A; Stäbler A; Nagel D; Lamerz R; Bartl R; Hiller E; Wendtner C; Bachner F; Reiser M
    Cancer; 2002 Sep; 95(6):1334-45. PubMed ID: 12216103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.
    Baur-Melnyk A; Buhmann S; Becker C; Schoenberg SO; Lang N; Bartl R; Reiser MF
    AJR Am J Roentgenol; 2008 Apr; 190(4):1097-104. PubMed ID: 18356461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
    Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
    Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of MRI for the diagnosis and prognosis of multiple myeloma.
    Baur-Melnyk A; Buhmann S; Dürr HR; Reiser M
    Eur J Radiol; 2005 Jul; 55(1):56-63. PubMed ID: 15950101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems.
    Fechtner K; Hillengass J; Delorme S; Heiss C; Neben K; Goldschmidt H; Kauczor HU; Weber MA
    Radiology; 2010 Oct; 257(1):195-204. PubMed ID: 20851941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma.
    Narquin S; Ingrand P; Azais I; Delwail V; Vialle R; Boucebci S; Tasu JP
    Diagn Interv Imaging; 2013 Jun; 94(6):629-36. PubMed ID: 23683788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates.
    Stäbler A; Baur A; Bartl R; Munker R; Lamerz R; Reiser MF
    AJR Am J Roentgenol; 1996 Oct; 167(4):1029-36. PubMed ID: 8819407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
    Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Estimation of diffuse bone marrow infiltration of the spine in multiple myeloma: correlation of MRT with histological results].
    Schmidt GP; Baur A; Stäbler A; Schoenberg SO; Steinborn M; Baltin V; Reiser MF
    Rofo; 2005 May; 177(5):745-50. PubMed ID: 15871089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging.
    Squillaci E; Bolacchi F; Altobelli S; Franceschini L; Bergamini A; Cantonetti M; Simonetti G
    Acta Radiol; 2015 Jun; 56(6):733-8. PubMed ID: 24973257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
    Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
    Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Magnetic resonance tomography in plasmacytoma: ranking of various sequences in diffuse and focal infiltration patterns].
    Baur A; Stäbler A; Steinborn M; Schnarkowski P; Pistitsch C; Lamerz R; Bartl R; Reiser M
    Rofo; 1998 Apr; 168(4):323-9. PubMed ID: 9589093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma.
    Dutoit JC; Vanderkerken MA; Verstraete KL
    Eur J Radiol; 2013 Sep; 82(9):1444-52. PubMed ID: 23726124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and clinical significance of beta-catenin in multiple myeloma].
    Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
    Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.